Side-by-side · Research reference
PancragenvsTestagen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED23/39 cited
BAnimal-MechanisticHUMAN-REVIEWED11/41 cited
Testagen
Bioregulator Peptide · Khavinson School
SQ · Abdomen · Cyclical
01Mechanism of Action
Parameter
Pancragen
Testagen
Primary target
Pancreatic acinar and islet cell differentiation pathwaysKhavinson 2013
Testicular tissue; proposed nuclear DNA interaction
Pathway
Transcription factor activation → Pdx1/Pax6/Pax4/Ptf1a/Foxa2/NKx2.2 upregulation → Cell differentiationKhavinson 2013
Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis)Fedoreyeva 2011
Downstream effect
Enhanced pancreatic beta-cell function, normalized insulin/C-peptide dynamics, improved glucose clearanceGoncharova 2014
Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interactionFedoreyeva 2011
Feedback intact?
Yes — preserves physiological glucose-insulin response
Unknown — no HPG axis data
Origin
Synthetic tetrapeptide derived from pancreatic tissue extracts (Khavinson bioregulator methodology)
Khavinson bioregulator school — isolated from testicular tissue peptide fractions
Antibody development
—
—
02Dosage Protocols
Parameter
Pancragen
Testagen
Primate dose (rhesus macaque)
50 μg / animal / dayGoncharova 2014
20–25-year-old females, 10-day IM protocol.
—
Effective concentration (in vitro)
0.05 ng/mLZakutskiĭ 2006
Organotypic tissue culture, both young and aged rat explants.
—
Evidence basis
Non-human primate RCT, in vitro cell cultureGoncharova 2015Khavinson 2013
Animal mechanistic / in vitro onlyFedoreyeva 2011
Diabetes model
STZ-induced diabetes (rat)
Evaluated via metabolic markers characterizing apoptosis.
—
Typical protocol (anecdotal)
—
100–200 mcg / day
No published human dosing studies; derived from Russian bioregulator practice.
Cycle length
—
10–20 days on, 10–14 days off
Bioregulator tradition uses pulsed cycles; no controlled data.
Reconstitution
—
Sterile water or bacteriostatic saline
Half-life
—
Unknown — likely minutes (short peptide)
04Side Effects & Safety
Parameter
Pancragen
Testagen
Reported adverse events
None documented in primate studies
—
Human safety data
No published human trials; clinical use limited to Russian gerontology protocols
—
Injection site reactions
—
Erythema, mild irritation (potential)
Systemic effects
—
Unknown — no human safety data
Hormonal impact
—
No published data on testosterone, LH, FSH effects
Long-term safety
—
Unknown — no long-term studies
Absolute Contraindications
Pancragen
—Testagen
- ·Active testicular malignancy
Relative Contraindications
Pancragen
- ·Active pancreatic malignancy (proliferation marker upregulation)
Testagen
- ·Hormone-sensitive cancers (no data; theoretical caution)
- ·Pregnant or breastfeeding (no data)
05Administration Protocol
Parameter
Pancragen
Testagen
1. Reconstitution
Lyophilised tetrapeptide reconstituted in sterile saline or water per manufacturer protocol. Concentration not specified in literature.
Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.
2. Route
Intramuscular injection. Primate studies used daily IM dosing for 10 consecutive days.Goncharova 2015
Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).
3. Timing
No specific timing constraints documented. Administered once daily in primate protocols.
Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.
4. Cycle structure
10-day treatment course. Restorative effects on pancreatic function persist for at least 3 weeks post-discontinuation.Goncharova 2014
Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.
5. Cycle protocol
—
10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.